Literature DB >> 2317900

Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease.

M H Crawford1, J Souchek, C A Oprian, D C Miller, S Rahimtoola, J C Giacomini, G Sethi, K E Hammermeister.   

Abstract

To determine how survival and clinical status were related to left ventricular (LV) size and systolic function after mitral valve replacement, 104 patients (48 mitral regurgitation [MR], 33 mitral stenosis [MS], and 23 MS/MR) with isolated mitral valve replacement were evaluated before and after surgery. Preoperative hemodynamic abnormalities by cardiac catheterization were improved 6 months after surgery in all three patient groups. The patients with MR exhibited reductions in LV end-diastolic volume index (EDVI) (117 +/- 51 to 89 +/- 27 ml/m2, p less than 0.001) and ejection fraction (EF) (0.56 +/- 0.15 to 0.45 +/- 0.13, p less than 0.001); however, the ratio of forward stroke volume to end-diastolic volume increased (0.32 +/- 0.21 to 0.45 +/- 0.17, p less than 0.001) because of the elimination of regurgitant volume. Survival analysis revealed that mortality was significantly higher in MS or MS/MR patients with postoperative EDVI more than 101 ml/m2 (p less than 0.001 and p less than 0.042, respectively) and in MR patients with postoperative EF less than or equal to 0.50 (p less than 0.031). Also, the majority of patients with MR or MS/MR and postoperative EDVI more than 101 ml/m2 and EF less than or equal to 0.50 were in New York Heart Association class III or IV. Multivariate logistic regression analysis in the patients with MR revealed that the strongest predictor of postoperative EF was preoperative EF (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2317900     DOI: 10.1161/01.cir.81.4.1173

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

Review 1.  Timing of mitral valve surgery.

Authors:  Maurice Enriquez-Sarano
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

Review 2.  Pathophysiology of valvular heart disease: implications for nuclear imaging.

Authors:  Blasé Carabello
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 3.  Timing of surgery in mitral regurgitation.

Authors:  Catherine M Otto
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

4.  A method for the morphological analysis of the regurgitant mitral valve using three dimensional echocardiography.

Authors:  A Macnab; N P Jenkins; I Ewington; B J M Bridgewater; T L Hooper; D L Greenhalgh; M R Patrick; S G Ray
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

Review 5.  Surgical reconstruction of the mitral valve.

Authors:  S M Tuladhar; P P Punjabi
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

6.  Evaluation of a semiautomatic software tool for left ventricular function analysis with 16-slice computed tomography.

Authors:  Marc Dewey; Mira Müller; Florian Teige; Bernd Hamm
Journal:  Eur Radiol       Date:  2005-06-17       Impact factor: 5.315

7.  Assessment of functional anatomy of the mitral valve in patients with mitral regurgitation with cine magnetic resonance imaging: comparison with transesophageal echocardiography and surgical results.

Authors:  A Stork; O Franzen; H Ruschewski; C Detter; K Müllerleile; P M Bansmann; G Adam; G K Lund
Journal:  Eur Radiol       Date:  2007-06-05       Impact factor: 5.315

8.  Preservation of left ventricular function in mitral valve surgery.

Authors:  S Westaby
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

9.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

10.  Selection of prosthetic heart valves.

Authors:  Robert P Gallegos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.